Biotechnology News and Research

RSS

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2011.

7 May 2011

Spherix effects 1-for-10 reverse stock split

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation, as amended, to effect a 1-for-10 reverse stock split of its common stock that will become effective at end of business today.

7 May 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer.

6 May 2011

NYU, LaSalle University develop new effective asthma-related anxiety tool

When children or adolescents with asthma and their parents become overly anxious about the disorder, it may impair their ability to manage the asthma effectively. A new, effective tool to assess asthma-related anxiety is described in an article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

6 May 2011

Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

Furiex Pharmaceuticals, Inc. today announced that two abstracts featuring its antibiotic candidate JNJ-Q2 will be presented at the 2011 joint meeting of the European Congress of Clinical Microbiology and Infectious Diseases and the International Congress of Chemotherapy.

6 May 2011

COIN hosts nanobiotechnology event on nanomedicines and the regulatory path

The Center of Innovation for Nanobiotechnology (COIN) today announced the upcoming NanoBio Executive Roundtable event to be hosted at RTP Foundation in Durham, NC on May 17, 2011. This Roundtable will tackle regulatory issues surrounding nanomedicine commercialization. The “Nanomedicines and the Regulatory Path” Roundtable will kick off with a presentation from Katherine Tyner, Ph.D., a Chemist in the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA).

5 May 2011

Fluidigm ships over 1 billion microscopic NanoFlex valves

Fluidigm today announced that its Singapore factory has manufactured and shipped more than 1 billion microscopic NanoFlex™ valves. Each NanoFlex valve is so small that it takes 10 to span the width of a human hair.

5 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 will be presented at the 2011 American Thoracic Society International Conference, being held May 13-18, 2011 in Denver, CO.

5 May 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

Anacor first quarter revenues increase to $2.2 million

Anacor Pharmaceuticals reviewed today its first quarter accomplishments and reported financial results for the quarter ended March 31, 2011.

5 May 2011

UCF to develop safe, inexpensive and effective polio vaccine

An innovative way of making vaccines at the University of Central Florida has attracted the support of the Bill & Melinda Gates Foundation for its potential to make vaccines lessexpensive, more effective and needle free.

5 May 2011

INC Research to acquire Kendle in all-cash transaction

INC Research, LLC, a therapeutically focused global contract research organization (CRO) privately held by Avista Capital Partners and Ontario Teachers' Pension Plan, and Kendle International Inc., today jointly announced a definitive merger agreement under which INC Research will acquire Kendle in an all-cash transaction with a total equity value of approximately $232 million.

5 May 2011

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Northwest Biotherapeutics today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal type of brain cancer.

4 May 2011

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that clinical data with PMX-60056 were presented at the American Heart Association's Arteriosclerosis, Thrombosis, and Vascular Biology Meeting in Chicago on April 28, 2011.

4 May 2011

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME Study of ILUVIEN for the treatment of Diabetic Macular Edema at the 2011 ARVO Annual Meeting.

4 May 2011

WWP2 protein appears to play a key role in tumor survival

A protein known as WWP2 appears to play a key role in tumor survival, a research team headed by a scientist at The University of Texas MD Anderson Cancer Center reports in an advance online publication of Nature Cell Biology.

4 May 2011

Techne decides to pay a dividend of $0.27 per share for quarter ended March 31, 2011

Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.27 per share for the quarter ended March 31, 2011.

From BiosPacific, Inc. 3 May 2011

Techne net earnings decrease 4.1% to $31.1 million for quarter ended March 31, 2011

Techne Corporation's consolidated pretax net earnings for the quarter ended March 31, 2011 increased 9.5% to $45.4 million compared with $41.4 million for the quarter ended March 31, 2010, mainly as a result of increased sales and foreign exchange transaction gains, partially offset by increased selling, general and administrative expenses.

From BiosPacific, Inc. 3 May 2011

Techne acquires Tocris Holdings

Techne Corporation announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries, a leading supplier of reagents for non-clinical life science research.

3 May 2011

Biotechnology News and Research

Enzon first quarter adjusted loss from continuing operations decreases to $4.2 million

Spherix effects 1-for-10 reverse stock split

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

NYU, LaSalle University develop new effective asthma-related anxiety tool

Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

COIN hosts nanobiotechnology event on nanomedicines and the regulatory path

Fluidigm ships over 1 billion microscopic NanoFlex valves

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

Anacor first quarter revenues increase to $2.2 million

UCF to develop safe, inexpensive and effective polio vaccine

INC Research to acquire Kendle in all-cash transaction

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

WWP2 protein appears to play a key role in tumor survival

Techne decides to pay a dividend of $0.27 per share for quarter ended March 31, 2011

Techne net earnings decrease 4.1% to $31.1 million for quarter ended March 31, 2011

Techne acquires Tocris Holdings

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News